Which has stronger valuation & earnings, DYN or VOR?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dyne Therapeutics N/A N/A -$446.21M -$3.22 N/A Vor Biopharma N/A N/A N/A N/A N/A

Is DYN or VOR more profitable?

Vor Biopharma's return on equity of 0.00% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dyne Therapeutics N/A -58.28% -46.77% Vor Biopharma N/A N/A N/A

Does the media prefer DYN or VOR?

In the previous week, Dyne Therapeutics had 6 more articles in the media than Vor Biopharma. MarketBeat recorded 9 mentions for Dyne Therapeutics and 3 mentions for Vor Biopharma. Dyne Therapeutics' average media sentiment score of 0.28 beat Vor Biopharma's score of 0.23 indicating that Dyne Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vor Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, ARQT or VOR?

Vor Biopharma has lower revenue, but higher earnings than Arcutis Biotherapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arcutis Biotherapeutics $376.07M 8.58 -$16.14M -$0.03 N/A Vor Biopharma N/A N/A N/A N/A N/A

Does the media refer more to ARQT or VOR?

In the previous week, Arcutis Biotherapeutics had 3 more articles in the media than Vor Biopharma. MarketBeat recorded 6 mentions for Arcutis Biotherapeutics and 3 mentions for Vor Biopharma. Arcutis Biotherapeutics' average media sentiment score of 0.86 beat Vor Biopharma's score of 0.23 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vor Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, VOR or ALMS?

Vor Biopharma has higher earnings, but lower revenue than Alumis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Alumis $24.05M 140.48 -$243.32M -$1.98 N/A

Is VOR or ALMS more profitable?

Vor Biopharma has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Vor Biopharma's return on equity of 0.00% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Vor Biopharma N/A N/A N/A Alumis -2,825.70% -88.79% -70.72%

Does the media favor VOR or ALMS?

In the previous week, Vor Biopharma and Vor Biopharma both had 3 articles in the media. Vor Biopharma's average media sentiment score of 0.23 beat Alumis' score of 0.00 indicating that Vor Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alumis 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, ADPT or VOR?

Vor Biopharma has lower revenue, but higher earnings than Adaptive Biotechnologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adaptive Biotechnologies $295.41M 11.48 -$59.50M -$0.33 N/A Vor Biopharma N/A N/A N/A N/A N/A

Does the media refer more to ADPT or VOR?

In the previous week, Adaptive Biotechnologies had 5 more articles in the media than Vor Biopharma. MarketBeat recorded 8 mentions for Adaptive Biotechnologies and 3 mentions for Vor Biopharma. Adaptive Biotechnologies' average media sentiment score of 0.48 beat Vor Biopharma's score of 0.23 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vor Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate VOR or GMTX?

Vor Biopharma currently has a consensus target price of $42.25, indicating a potential upside of 105.20%. Given Vor Biopharma's stronger consensus rating and higher probable upside, research analysts plainly believe Vor Biopharma is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vor Biopharma 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 2.82 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, VOR or GMTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A

Is VOR or GMTX more profitable?

Vor Biopharma's return on equity of 0.00% beat Gemini Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vor Biopharma N/A N/A N/A Gemini Therapeutics N/A -38.78% -35.88%

Vor Biopharma (VOR) Competitors

$20.59 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$20.30 -0.29 (-1.43%)

As of 07/2/2026 07:52 PM Eastern

Compare

VOR vs. DYN, ARQT, ALMS, ADPT, and GMTX

Should you buy Vor Biopharma stock or one of its competitors? MarketBeat compares Vor Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vor Biopharma include Dyne Therapeutics (DYN), Arcutis Biotherapeutics (ARQT), Alumis (ALMS), Adaptive Biotechnologies (ADPT), and Gemini Therapeutics (GMTX). These companies are all part of the "pharmaceutical products" industry.

How does Vor Biopharma compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Vor Biopharma (NASDAQ:VOR) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by insiders. Comparatively, 0.3% of Vor Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Dyne Therapeutics has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market.

Vor Biopharma's return on equity of 0.00% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-58.28%	-46.77%
Vor Biopharma	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

In the previous week, Dyne Therapeutics had 6 more articles in the media than Vor Biopharma. MarketBeat recorded 9 mentions for Dyne Therapeutics and 3 mentions for Vor Biopharma. Dyne Therapeutics' average media sentiment score of 0.28 beat Vor Biopharma's score of 0.23 indicating that Dyne Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vor Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dyne Therapeutics currently has a consensus target price of $34.17, suggesting a potential upside of 48.10%. Vor Biopharma has a consensus target price of $42.25, suggesting a potential upside of 105.20%. Given Vor Biopharma's higher probable upside, analysts clearly believe Vor Biopharma is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

Summary

Dyne Therapeutics and Vor Biopharma tied by winning 5 of the 10 factors compared between the two stocks.

How does Vor Biopharma compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Vor Biopharma (NASDAQ:VOR) are both pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

Arcutis Biotherapeutics currently has a consensus target price of $34.00, indicating a potential upside of 31.73%. Vor Biopharma has a consensus target price of $42.25, indicating a potential upside of 105.20%. Given Vor Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Vor Biopharma is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

97.3% of Vor Biopharma shares are owned by institutional investors. 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Comparatively, 0.3% of Vor Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Vor Biopharma has lower revenue, but higher earnings than Arcutis Biotherapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	8.58	-$16.14M	-$0.03	N/A
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Vor Biopharma has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. Vor Biopharma's return on equity of 0.00% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%
Vor Biopharma	N/A	N/A	N/A

In the previous week, Arcutis Biotherapeutics had 3 more articles in the media than Vor Biopharma. MarketBeat recorded 6 mentions for Arcutis Biotherapeutics and 3 mentions for Vor Biopharma. Arcutis Biotherapeutics' average media sentiment score of 0.86 beat Vor Biopharma's score of 0.23 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vor Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arcutis Biotherapeutics has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market.

Summary

Vor Biopharma beats Arcutis Biotherapeutics on 9 of the 13 factors compared between the two stocks.

How does Vor Biopharma compare to Alumis?

Vor Biopharma (NASDAQ:VOR) and Alumis (NASDAQ:ALMS) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

Vor Biopharma has higher earnings, but lower revenue than Alumis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Alumis	$24.05M	140.48	-$243.32M	-$1.98	N/A

Vor Biopharma has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Vor Biopharma's return on equity of 0.00% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Alumis	-2,825.70%	-88.79%	-70.72%

97.3% of Vor Biopharma shares are held by institutional investors. 0.3% of Vor Biopharma shares are held by company insiders. Comparatively, 33.7% of Alumis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Vor Biopharma and Vor Biopharma both had 3 articles in the media. Vor Biopharma's average media sentiment score of 0.23 beat Alumis' score of 0.00 indicating that Vor Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alumis	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vor Biopharma presently has a consensus price target of $42.25, indicating a potential upside of 105.20%. Alumis has a consensus price target of $40.30, indicating a potential upside of 52.08%. Given Vor Biopharma's higher possible upside, equities analysts clearly believe Vor Biopharma is more favorable than Alumis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Vor Biopharma has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market. Comparatively, Alumis has a beta of -0.73, suggesting that its stock price is 173% less volatile than the broader market.

Summary

Vor Biopharma beats Alumis on 8 of the 12 factors compared between the two stocks.

How does Vor Biopharma compare to Adaptive Biotechnologies?

Adaptive Biotechnologies (NASDAQ:ADPT) and Vor Biopharma (NASDAQ:VOR) are both pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Vor Biopharma has lower revenue, but higher earnings than Adaptive Biotechnologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$295.41M	11.48	-$59.50M	-$0.33	N/A
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Adaptive Biotechnologies presently has a consensus target price of $20.50, indicating a potential downside of 3.26%. Vor Biopharma has a consensus target price of $42.25, indicating a potential upside of 105.20%. Given Vor Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Vor Biopharma is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

Vor Biopharma has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -16.82%. Vor Biopharma's return on equity of 0.00% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%
Vor Biopharma	N/A	N/A	N/A

In the previous week, Adaptive Biotechnologies had 5 more articles in the media than Vor Biopharma. MarketBeat recorded 8 mentions for Adaptive Biotechnologies and 3 mentions for Vor Biopharma. Adaptive Biotechnologies' average media sentiment score of 0.48 beat Vor Biopharma's score of 0.23 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vor Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.2% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are owned by institutional investors. 5.7% of Adaptive Biotechnologies shares are owned by insiders. Comparatively, 0.3% of Vor Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Adaptive Biotechnologies has a beta of 2.07, indicating that its stock price is 107% more volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.69, indicating that its stock price is 69% more volatile than the broader market.

Summary

Vor Biopharma beats Adaptive Biotechnologies on 7 of the 13 factors compared between the two stocks.

How does Vor Biopharma compare to Gemini Therapeutics?

Vor Biopharma (NASDAQ:VOR) and Gemini Therapeutics (NASDAQ:GMTX) are both pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 0.3% of Vor Biopharma shares are held by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Vor Biopharma currently has a consensus target price of $42.25, indicating a potential upside of 105.20%. Given Vor Biopharma's stronger consensus rating and higher probable upside, research analysts plainly believe Vor Biopharma is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Vor Biopharma has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the broader market.

Vor Biopharma's return on equity of 0.00% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Gemini Therapeutics	N/A	-38.78%	-35.88%

In the previous week, Vor Biopharma had 3 more articles in the media than Gemini Therapeutics. MarketBeat recorded 3 mentions for Vor Biopharma and 0 mentions for Gemini Therapeutics. Vor Biopharma's average media sentiment score of 0.23 beat Gemini Therapeutics' score of 0.00 indicating that Vor Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Vor Biopharma	Neutral
Gemini Therapeutics	Neutral

Summary

Vor Biopharma beats Gemini Therapeutics on 10 of the 11 factors compared between the two stocks.

Get Vor Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VOR vs. The Competition

Export

Metric	Vor Biopharma	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$1.12B	$538.08M	$5.20B	$12.48B
Dividend Yield	N/A	N/A	16.11%	6.52%
P/E Ratio	N/A	N/A	23.91	24.70
Price / Sales	N/A	388.95	217.06	99.46
Price / Cash	N/A	N/A	35.06	57.09
Price / Book	N/A	2.94	13.25	6.46
Net Income	N/A	-$81.71M	$113.80M	$337.01M
7 Day Performance	27.89%	7.17%	0.93%	1.69%
1 Month Performance	56.46%	21.82%	1.08%	3.81%
1 Year Performance	-46.10%	-72.26%	10.03%	23.90%

Vor Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VOR Vor Biopharma	2.2999 of 5 stars	$20.59 flat	$42.25 +105.2%	-46.1%	$1.12B	N/A	N/A	140	News Coverage Analyst Upgrade Gap Down High Trading Volume
DYN Dyne Therapeutics	2.7602 of 5 stars	$20.94 +1.6%	$34.17 +63.2%	+154.9%	$3.46B	N/A	N/A	100	Insider Trade Gap Down High Trading Volume
ARQT Arcutis Biotherapeutics	3.5658 of 5 stars	$27.00 +1.2%	$34.00 +25.9%	+88.2%	$3.38B	$376.07M	N/A	150	High Trading Volume
ALMS Alumis	2.4314 of 5 stars	$26.41 +5.5%	$40.30 +52.6%	+706.7%	$3.37B	$24.05M	N/A	N/A	News Coverage High Trading Volume
ADPT Adaptive Biotechnologies	2.5463 of 5 stars	$20.97 +3.6%	$20.33 -3.1%	+76.9%	$3.35B	$276.98M	N/A	790	Insider Trade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VOR) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vor Biopharma (VOR) Competitors

VOR vs. DYN, ARQT, ALMS, ADPT, and GMTX

How does Vor Biopharma compare to Dyne Therapeutics?

Summary

How does Vor Biopharma compare to Arcutis Biotherapeutics?

Summary

How does Vor Biopharma compare to Alumis?

Summary

How does Vor Biopharma compare to Adaptive Biotechnologies?

Summary

How does Vor Biopharma compare to Gemini Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VOR vs. The Competition

Vor Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vor Biopharma (VOR) Competitors

VOR vs. DYN, ARQT, ALMS, ADPT, and GMTX

How does Vor Biopharma compare to Dyne Therapeutics?

Do insiders and institutionals hold more shares of DYN or VOR?

Which has more volatility and risk, DYN or VOR?

Is DYN or VOR more profitable?

Which has stronger valuation & earnings, DYN or VOR?

Does the media prefer DYN or VOR?

Do analysts prefer DYN or VOR?

Summary

How does Vor Biopharma compare to Arcutis Biotherapeutics?

Do analysts prefer ARQT or VOR?

Do insiders & institutionals believe in ARQT or VOR?

Which has stronger earnings & valuation, ARQT or VOR?

Is ARQT or VOR more profitable?

Does the media refer more to ARQT or VOR?

Which has more volatility & risk, ARQT or VOR?

Summary

How does Vor Biopharma compare to Alumis?

Which has stronger valuation and earnings, VOR or ALMS?

Is VOR or ALMS more profitable?

Do institutionals & insiders have more ownership in VOR or ALMS?

Does the media favor VOR or ALMS?

Do analysts rate VOR or ALMS?

Which has more volatility and risk, VOR or ALMS?

Summary

How does Vor Biopharma compare to Adaptive Biotechnologies?

Which has higher earnings and valuation, ADPT or VOR?

Do analysts recommend ADPT or VOR?

Is ADPT or VOR more profitable?

Does the media refer more to ADPT or VOR?

Do insiders & institutionals have more ownership in ADPT or VOR?

Which has more volatility and risk, ADPT or VOR?

Summary

How does Vor Biopharma compare to Gemini Therapeutics?

Do insiders and institutionals have more ownership in VOR or GMTX?

Do analysts rate VOR or GMTX?

Which has higher valuation & earnings, VOR or GMTX?

Which has more risk and volatility, VOR or GMTX?

Is VOR or GMTX more profitable?

Does the media favor VOR or GMTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VOR vs. The Competition

Vor Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools